je.st
news
Valeant raises offer for Dendreon assets to US$400 million to remain lead bidder
2015-02-05 18:29:47| Biotech - Topix.net
Valeant Pharmaceuticals International has raised its offer for the Provenge prostate cancer vaccine and other assets of U.S. drugmaker Dendreon Corp. by $100 million to $400 million. The Quebec-based company is the lead bidder in an auction supervised by a U.S. bankruptcy court.
Tags: offer
lead
million
remain
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||